Amendments to the Claims:

The following is a complete list of claims indicating the changes incorporated by the present amendment and replacing all prior versions of the claims. Any claims canceled herein and all deletions made in claims that are not canceled herein are done so without prejudice to being re-instituted at a later date in this or a related application.

Listing of Claims:

1. **(Currently Amended)** A compound according to the formula



and the pharmaceutically acceptable salts thereof,

~~**wherein**~~

~~**each Z is independently N or C(R^1), with the proviso that no more than 2 Z's in any one aromatic ring are N;**~~

wherein the moiety:



is selected from the group consisting of





and

; and

wherein the moiety:

is selected from the group consisting of



and

;

~~**Y is O, N, or S;**~~

~~**Q is N or C(R^1), with the proviso that Q is C(R^1) when Y is N;**~~

~~**Ar is an unsubstituted or substituted aromatic or heteroaromatic 5- or 6-member ring;**~~

each R^1 is independently H, halogen, OH, or a C_1 to C_{12} alkyl **or** heteroalkyl moiety;

each R^2 is independently H or a C_1 to C_{18} alkyl or heteroalkyl moiety or the two R^2's taken together with the nitrogen atom to which they are attached form a substituted or unsubstituted heteroalkyl 5 to 7 member ring;

wherein the moiety:

is selected from the group consisting of



wherein one of X^1, X^2, and X^3 is a ring vertex selected from the group consisting of -O-, -S-, and $-NR^8$-, and the other two of X^1, X^2, and X^3 are ring vertices selected from the group consisting of =N- and $=CR^7$-;

each R^7 is independently H, F, Cl, Br, I, CN, OH, NO_2, NH_2, a substituted or unsubstituted (C_1-C_{12})alkyl group, a substituted or unsubstituted (C_1-C_{12})alkoxy group, or a substituted or unsubstituted (C_1-C_{12})heteroalkyl group;

R^8 is H, a substituted or unsubstituted (C_1-C_{12})alkyl group, or a substituted or unsubstituted (C_1-C_{12})heteroalkyl group; and

R^3 is H or a C_1 to C_6 alkyl moiety;

with the proviso that at least one group R^1, R^2, or R^3 contains an alkyl amine group or a quaternary nitrogen group.

2. (Original) A compound according to claim 1, wherein at least one group R^2 contains an alkyl amine group.

3. **(Canceled)**

4. (Original) A compound according to claim 1 or 2, wherein



is selected from the group consisting of



and



5. **(Canceled)**

6. (Original) A compound according to claim 1 or 2, wherein

is selected from the group consisting of

and

7. **(Canceled)**

8. (Original) A compound according to claim 1 or 2, wherein

is selected from the group consisting of

and



9. (Original) A compound according to claim 1 or 2, wherein R^3 is H.

10. (Original) A compound according to a formula selected from the group consisting of


















and



and the pharmaceutically acceptable salts thereof,

wherein each R^2 is independently H or a C_1 to C_{18} alkyl or heteroalkyl moiety or the two R^2's taken together with the nitrogen atom to which they are attached form a substituted or unsubstituted heteroalkyl 5 to 7 member ring; at least one group R^2 containing an alkyl amine group.

11. (Original) A compound according to claim 1, 2 or 10, wherein $N(R^2)_2$ is selected from the group consisting of







and



12. (Original) A compound according to claim 1, having a minimum inhibitory concentration of 4 μg/mL or less against at least one of *Staphylococcus aureus* (ATCC 27660), *Streptococcus pneumoniae* (ATCC 51422), and *Enterococcus faecium* (ATCC 51559).

13. **(Currently Amended)** A method of treating a **Gram-positive** bacterial infection in a mammal, comprising administering to a patient in need of such treatment an effective amount of a compound according to claim 1, 2, or 10.

14. (Original) A method according to claim 13, wherein the bacterial infection is an infection by drug resistant bacteria.

15. (Original) A method according to claim 14, wherein the drug resistant bacteria is MRSA, PRSP, or VRE.

16. **(Canceled)** The use of a compound according to claim 1, 2, or 8 for the preparation of a medicament for the treatment of a bacterial infection in a mammal.

17. (New) A compound according to claim 1, wherein R^1 is H or CH_3.